Figure 4.
ICG-001 differentiates leukemia cells. Murine B220+CD19+BCR-ABL1 p210+ ALL cells were treated with ICG-001 (5 or 10µM) or Imatinib (1µM) or Control (media only) for 72 hours. (a) B220, CD19 and (b) Ig κ light chain were detected by flow cytometry and (c) quantified. (d) Cell numbers were determined by trypan blue exclusion of dead cells. (e) Co-immunoprecipitation determines the interaction between endogenous β-catenin and CBP or p300. Murine BCR-ABL1 p210+ ALL cells were treated with ICG-001 at 10µM (ICG) or its vehicle control DMSO (D, 0.1%) for 48 hours. Nuclear proteins were subsequently incubated with CBP and p300 antibody. Western blot was performed using the antibodies against β-catenin.